WO2000038730A3 - Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia - Google Patents

Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia Download PDF

Info

Publication number
WO2000038730A3
WO2000038730A3 PCT/US1999/030693 US9930693W WO0038730A3 WO 2000038730 A3 WO2000038730 A3 WO 2000038730A3 US 9930693 W US9930693 W US 9930693W WO 0038730 A3 WO0038730 A3 WO 0038730A3
Authority
WO
WIPO (PCT)
Prior art keywords
cyclooxygenase
inhibitor
neoplasia
combination therapy
antineoplastic agents
Prior art date
Application number
PCT/US1999/030693
Other languages
French (fr)
Other versions
WO2000038730A2 (en
Inventor
John P Mckearn
Gary Gordon
James J Cunningham
Stephen T Gately
Alane T Koki
Jaime L Masferrer
Original Assignee
Searle & Co
John P Mckearn
Gary Gordon
James J Cunningham
Stephen T Gately
Alane T Koki
Jaime L Masferrer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority to EA200100572A priority Critical patent/EA006294B1/en
Priority to DE69930764T priority patent/DE69930764D1/en
Priority to KR1020017008112A priority patent/KR20010110310A/en
Priority to JP2000590681A priority patent/JP2002533416A/en
Application filed by Searle & Co, John P Mckearn, Gary Gordon, James J Cunningham, Stephen T Gately, Alane T Koki, Jaime L Masferrer filed Critical Searle & Co
Priority to BR9916518-0A priority patent/BR9916518A/en
Priority to PL99350291A priority patent/PL350291A1/en
Priority to HU0104814A priority patent/HUP0104814A3/en
Priority to AU23805/00A priority patent/AU783992B2/en
Priority to IL14387099A priority patent/IL143870A0/en
Priority to EP99967543A priority patent/EP1140192B1/en
Priority to CA002356606A priority patent/CA2356606A1/en
Publication of WO2000038730A2 publication Critical patent/WO2000038730A2/en
Publication of WO2000038730A3 publication Critical patent/WO2000038730A3/en
Priority to NO20013155A priority patent/NO20013155L/en
Priority to US10/150,546 priority patent/US20030119895A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/415—1,2-Diazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/42—Oxazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/243—Platinum; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K41/00—Medicinal preparations obtained by treating materials with wave energy or particle radiation ; Therapies using these preparations
    • A61K41/0038—Radiosensitizing, i.e. administration of pharmaceutical agents that enhance the effect of radiotherapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/14—Drugs for genital or sexual disorders; Contraceptives for lactation disorders, e.g. galactorrhoea
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Inorganic Chemistry (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pulmonology (AREA)
  • Urology & Nephrology (AREA)
  • Surgery (AREA)
  • Pregnancy & Childbirth (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Hydrogenated Pyridines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pyrane Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Peptides Or Proteins (AREA)
  • Radiation-Therapy Devices (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyridine Compounds (AREA)

Abstract

The present invention provides methods to treat or prevent neoplasia disorders in a mammal using a combination of a cyclooxygenase-2 inhibitor and an antineoplastic agent.
PCT/US1999/030693 1998-12-23 1999-12-22 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia WO2000038730A2 (en)

Priority Applications (13)

Application Number Priority Date Filing Date Title
PL99350291A PL350291A1 (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
KR1020017008112A KR20010110310A (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
JP2000590681A JP2002533416A (en) 1998-12-23 1999-12-22 Methods of using cyclooxygenase-2 inhibitors and one or more antineoplastic agents as combination therapy in the treatment of neoplasia
AU23805/00A AU783992B2 (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
BR9916518-0A BR9916518A (en) 1998-12-23 1999-12-22 A method for treating or preventing a neoplasm disorder in a mammal in need of such treatment or prevention, and a combination comprising a cyclooxygenase-2 inhibitor and one or more antineoplastic agents.
DE69930764T DE69930764D1 (en) 1998-12-23 1999-12-22 USE OF CYCLOOXYGENASE-2 INHIBITOR CELECOXIB AND CAPECITABINE FOR COMBINATION TREATMENT OF NEOPLASIA
HU0104814A HUP0104814A3 (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EA200100572A EA006294B1 (en) 1998-12-23 1999-12-22 Use a celecoxib and gemcitabine combination in a combined method for treating pancreas
IL14387099A IL143870A0 (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
EP99967543A EP1140192B1 (en) 1998-12-23 1999-12-22 Use of the cyclooxygenase-2 inhibitor celecoxib and capecitabine for combination therapy in neoplasia
CA002356606A CA2356606A1 (en) 1998-12-23 1999-12-22 Method of using a cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
NO20013155A NO20013155L (en) 1998-12-23 2001-06-22 Method using cyclooxygenase-2 inhibitor and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
US10/150,546 US20030119895A1 (en) 1998-12-23 2002-05-16 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11378698P 1998-12-23 1998-12-23
US60/113,786 1998-12-23

Related Child Applications (4)

Application Number Title Priority Date Filing Date
US09857873 A-371-Of-International 2001-10-05
US10/150,546 Continuation-In-Part US20030119895A1 (en) 1998-12-23 2002-05-16 Methods using a combination of a 3-heteroaryl-2-indolinone and a cyclooxygenase-2 inhibitor for the treatment of neoplasia
US10/212,523 Continuation-In-Part US20030203956A1 (en) 1998-12-23 2002-08-05 Method of using a cyclooxygenase-2 inhibitor and one or more ornithine decarboxylase inhibitors as a combination therapy in the treatment of neoplasia
US10/945,422 Continuation US20050037090A1 (en) 1998-12-23 2004-09-20 Combination therapy including a cyclooxygenase-2 inhibitor and an antineoplastic agent

Publications (2)

Publication Number Publication Date
WO2000038730A2 WO2000038730A2 (en) 2000-07-06
WO2000038730A3 true WO2000038730A3 (en) 2000-11-02

Family

ID=22351515

Family Applications (8)

Application Number Title Priority Date Filing Date
PCT/US1999/030670 WO2000038665A2 (en) 1998-12-23 1999-12-22 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PCT/US1999/030700 WO2000038719A1 (en) 1998-12-23 1999-12-22 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
PCT/US1999/030692 WO2000038786A2 (en) 1998-12-23 1999-12-22 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
PCT/US1999/030699 WO2000038718A2 (en) 1998-12-23 1999-12-22 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
PCT/US1999/030621 WO2000038715A2 (en) 1998-12-23 1999-12-22 Use of an integrin antagonist and radiation in the treatment of neoplasia
PCT/US1999/030776 WO2000037107A2 (en) 1998-12-23 1999-12-22 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia
PCT/US1999/030693 WO2000038730A2 (en) 1998-12-23 1999-12-22 Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
PCT/US1999/030676 WO2000038717A2 (en) 1998-12-23 1999-12-22 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia

Family Applications Before (6)

Application Number Title Priority Date Filing Date
PCT/US1999/030670 WO2000038665A2 (en) 1998-12-23 1999-12-22 Use of an integrin antagonist and one or more antineoplastic agents as a combination therapy in the treatment of neoplasia
PCT/US1999/030700 WO2000038719A1 (en) 1998-12-23 1999-12-22 Use of a matrix metalloproteinase inhibitor and an integrin antagonist in the treatment of neoplasia
PCT/US1999/030692 WO2000038786A2 (en) 1998-12-23 1999-12-22 Use of cyclooxygenase 2 inhibitor and an integrin antagonist as a combination therapy in the treatment of neoplasia
PCT/US1999/030699 WO2000038718A2 (en) 1998-12-23 1999-12-22 Use of matrix metalloproteinase inhibitor together with an antineoplastic agents, optionally also together with radiation, in the treatment of neoplasia
PCT/US1999/030621 WO2000038715A2 (en) 1998-12-23 1999-12-22 Use of an integrin antagonist and radiation in the treatment of neoplasia
PCT/US1999/030776 WO2000037107A2 (en) 1998-12-23 1999-12-22 Use of cyclooxygenase-2 inhibitor, a matrix metallaproteinase inhibitor, an antineoplastic agent and optionally radiation as a combination treatment of neoplasia

Family Applications After (1)

Application Number Title Priority Date Filing Date
PCT/US1999/030676 WO2000038717A2 (en) 1998-12-23 1999-12-22 Use of a matrix metalloproteinase inhibitor and radiation as a combined treatment of neoplasia

Country Status (20)

Country Link
US (1) US6689787B1 (en)
EP (8) EP1140179A2 (en)
JP (8) JP2002533404A (en)
KR (2) KR20010110310A (en)
CN (3) CN1371286A (en)
AT (1) ATE322290T1 (en)
AU (8) AU2713500A (en)
BR (2) BR9916536A (en)
CA (8) CA2356606A1 (en)
CZ (2) CZ20012320A3 (en)
DE (1) DE69930764D1 (en)
EA (2) EA006294B1 (en)
HU (2) HUP0104747A3 (en)
IL (2) IL143870A0 (en)
MX (1) MXPA01006499A (en)
NO (2) NO20013155L (en)
PL (2) PL350291A1 (en)
TR (1) TR200102499T2 (en)
WO (8) WO2000038665A2 (en)
ZA (2) ZA200105055B (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023338B2 (en) 2006-09-26 2015-05-05 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US9095538B2 (en) 2006-09-28 2015-08-04 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods

Families Citing this family (115)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6696449B2 (en) 1997-03-04 2004-02-24 Pharmacia Corporation Sulfonyl aryl hydroxamates and their use as matrix metalloprotease inhibitors
US7115632B1 (en) * 1999-05-12 2006-10-03 G. D. Searle & Co. Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US6794511B2 (en) 1997-03-04 2004-09-21 G. D. Searle Sulfonyl aryl or heteroaryl hydroxamic acid compounds
US20030225150A1 (en) * 1997-04-21 2003-12-04 Pharmacia Corporation Method of using a COX-2 inhibitor and a topoisomerase II inhibitor as a combination therapy in the treatment of neoplasia
US20040072889A1 (en) * 1997-04-21 2004-04-15 Pharmacia Corporation Method of using a COX-2 inhibitor and an alkylating-type antineoplastic agent as a combination therapy in the treatment of neoplasia
US6077850A (en) * 1997-04-21 2000-06-20 G.D. Searle & Co. Substituted benzopyran analogs for the treatment of inflammation
US7029652B2 (en) * 1998-09-16 2006-04-18 The Regents Of The University Of California Method of treating tumors
US20040053900A1 (en) * 1998-12-23 2004-03-18 Pharmacia Corporation Method of using a COX-2 inhibitor and an aromatase inhibitor as a combination therapy
US20020103141A1 (en) * 1998-12-23 2002-08-01 Mckearn John P. Antiangiogenic combination therapy for the treatment of cancer
US6800646B1 (en) 1999-02-08 2004-10-05 Pharmacia Corporation Sulfamato hydroxamic acid metalloprotease inhibitor
EE200100410A (en) * 1999-02-08 2002-12-16 G.D. Searle & Co. Sulphamate hydroxamic acid metalloprotease inhibitor
CA2373500A1 (en) * 1999-05-12 2000-11-23 G.D. Searle & Co. Hydroxamic acid derivatives as matrix metalloprotease inhibitors
CA2373931A1 (en) 1999-05-17 2000-11-23 Richard Love Dfmo and celecoxib in combination for cancer chemoprevention and therapy
US7141581B2 (en) 1999-07-02 2006-11-28 Agouron Pharmaceuticals, Inc. Indazole compounds and pharmaceutical compositions for inhibiting protein kinases, and methods for their use
GB9920548D0 (en) * 1999-08-31 1999-11-03 Rhone Poulenc Rorer Sa Treatment of hepatocellular carcinoma
CN1391484A (en) * 1999-09-15 2003-01-15 惠氏公司 Method of potentiating chemotherapy and treating solid tumors
US7465754B1 (en) 1999-09-15 2008-12-16 Wyeth Method of potentiating chemotherapy and treating solid tumors
WO2001035956A1 (en) * 1999-11-15 2001-05-25 Advanced Research And Technology Institute, Inc. USE OF NSAIDs FOR THE TREATMENT OF PANCREATIC CANCER
JP4039856B2 (en) 2000-02-03 2008-01-30 エーザイ・アール・アンド・ディー・マネジメント株式会社 Integrin expression inhibitor
WO2001064110A1 (en) * 2000-02-28 2001-09-07 Zila, Inc. Method for detecting and killing epithelial cancer cells
BR0109499A (en) 2000-03-24 2002-12-10 Novartis Ag Enhanced neovascularization treatment
EP1138680A1 (en) * 2000-03-29 2001-10-04 Pfizer Products Inc. Gem substituted sulfonyl hydroxamic acids as MMP inhibitors
WO2001096307A2 (en) 2000-06-15 2001-12-20 Pharmacia Corporation Cycloalkyl alkanoic acids as integrin receptor antagonists
AU7311501A (en) 2000-06-29 2002-03-22 Quick Med Technologies Inc Cosmetic composition and method
US6531494B1 (en) 2001-08-29 2003-03-11 Pharmacia Corporation Gem-substituted αvβ3 antagonists
AR034142A1 (en) * 2000-09-08 2004-02-04 Sloan Kettering Inst Cancer A PHARMACEUTICAL COMPOSITION, METHOD FOR MANUFACTURING A MEDICINAL BASED ON SUCH COMPOSITION AND USE OF THE COMPOSITION
AU8986501A (en) * 2000-09-08 2002-03-22 Pharmacia & Upjohn Spa Exemestane as chemopreventing agent
PT1377298E (en) * 2001-01-26 2006-12-29 Pharmacia & Upjohn Co Llc Exemestane for treating hormono-dependent disorders
US7312237B2 (en) 2001-03-14 2007-12-25 Bristol-Myers Squibb Co. Combination of epothilone analogs and chemotherapeutic agents for the treatment of prolilferative diseases
US20030105144A1 (en) 2001-04-17 2003-06-05 Ping Gao Stabilized oral pharmaceutical composition
EP2292251A1 (en) 2001-04-24 2011-03-09 Merck Patent GmbH Combination therapy using anti-angiogenic agents and TNF-alpha
US6872730B2 (en) 2001-04-27 2005-03-29 3-Dimensional Pharmaceuticals, Inc. Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
WO2002089824A1 (en) * 2001-05-03 2002-11-14 F. Hoffmann-La Roche Ag Combination of a gelatinase inhibitor and an anti-tumor agent, and uses thereof
US6995171B2 (en) 2001-06-21 2006-02-07 Agouron Pharmaceuticals, Inc. Bicyclic pyrimidine and pyrimidine derivatives useful as anticancer agents
US6683078B2 (en) 2001-07-19 2004-01-27 Pharmacia Corporation Use of sulfonyl aryl or heteroaryl hydroxamic acids and derivatives thereof as aggrecanase inhibitors
JP2005504759A (en) * 2001-07-23 2005-02-17 エピダウロス・バイオテクノロジー・アクチェンゲゼルシャフト Means and method for improving cancer treatment based on CYP3A5
AU2002363089B2 (en) * 2001-10-19 2006-02-16 Novartis Ag Pharmaceutical composition for use for the treatment of malignancies comprising in combination a bisphosphonates, a COX-2 inhibitor and a taxol
IL161462A0 (en) * 2001-10-25 2004-09-27 Novartis Ag Combinations comprising a selective cyclooxygenase-2 inhibitor
SI1450799T1 (en) * 2001-12-03 2007-02-28 Bayer Pharmaceuticals Corp Aryl urea compounds in combination with other cytostatic or cytotoxic agents for treating human cancers
US20030143165A1 (en) * 2002-01-25 2003-07-31 Allan Evans NSAID-containing topical formulations that demonstrate chemopreventive activity
GB0204756D0 (en) * 2002-02-28 2002-04-17 Novartis Ag Organic compounds
CA2478050A1 (en) 2002-03-01 2003-09-12 Pfizer Inc. Indolyl-urea derivatives of thienopyridines useful as anti-angiogenic agents
JP2005533001A (en) * 2002-03-04 2005-11-04 メディミューン，インコーポレーテッド Method for preventing or treating cancer in which integrin αvβ3 antagonist is administered in combination with other substances
US20050232915A1 (en) * 2002-03-08 2005-10-20 Motowo Nakajima Matrix metalloproteinase inhibitors in combination with hypothermia and/or radiotherapy for the treatment of cancer
JP2005531520A (en) 2002-03-28 2005-10-20 メルク　エンド　カムパニー　インコーポレーテッド Substituted 2,3-diphenylpyridines
WO2003091247A2 (en) 2002-04-25 2003-11-06 Pharmacia Corporation Piperidinyl-and piperazinyl-sulfonylmethyl hydroxamic acids and their use as protease inhibitors
UA77303C2 (en) 2002-06-14 2006-11-15 Pfizer Derivatives of thienopyridines substituted by benzocondensed heteroarylamide useful as therapeutic agents, pharmaceutical compositions and methods for their use
JP2006503812A (en) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination of an allosteric carboxyl matrix metalloproteinase-13 inhibitor with a selective cyclooxygenase-2 inhibitor that is not celecoxib or valdecoxib
JP2006503811A (en) * 2002-07-17 2006-02-02 ワーナー−ランバート・カンパニー、リミテッド、ライアビリティ、カンパニー Combination of allosteric carboxyl matrix metalloproteinase-13 inhibitor with celecoxib or valdecoxib
ES2362998T3 (en) * 2002-08-19 2011-07-18 Pfizer Inc. COMBINATION THERAPY FOR HYPERPROLIFERATIVE DISEASES.
MX367615B (en) 2002-09-06 2019-08-28 Cerulean Pharma Inc Cyclodextrin-based polymers for delivering the therapeutic agents covalently bound thereto.
MXPA05006676A (en) 2002-12-19 2005-08-16 Pfizer 2-(1h-indazol-6-ylamino)-benzamide compounds as protein kinases inhibitors useful for the treatment of ophtalmic diseases.
BRPI0408518A (en) * 2003-03-18 2006-03-07 Pharmacia Italia Spa combination therapy comprising nemorubicin and a cyclooxygenase-2 inhibitor
DE10313272A1 (en) * 2003-03-24 2004-10-21 Baxter Healthcare S.A. Using hexadecylphosphocholine for treatment of actinic keratosis, by topical application as aqueous solution
US20050043233A1 (en) 2003-04-29 2005-02-24 Boehringer Ingelheim International Gmbh Combinations for the treatment of diseases involving cell proliferation, migration or apoptosis of myeloma cells or angiogenesis
PT1534305E (en) 2003-05-07 2007-02-28 Osteologix As Treating cartilage / bone conditions with water-soluble strontium salts
US7008953B2 (en) 2003-07-30 2006-03-07 Agouron Pharmaceuticals, Inc. 3, 5 Disubstituted indazole compounds, pharmaceutical compositions, and methods for mediating or inhibiting cell proliferation
MXPA06002296A (en) 2003-08-29 2006-05-22 Pfizer Thienopyridine-phenylacet amides and their derivatives useful as new anti-angiogenic agents.
GB0321999D0 (en) * 2003-09-19 2003-10-22 Cancer Rec Tech Ltd Anti-cancer combinations
US7939090B2 (en) 2003-10-21 2011-05-10 Cedars-Sinai Medical Center System and method for the treatment of cancer, including cancers of the central nervous system
BRPI0418102A (en) 2003-12-23 2007-04-27 Pfizer quinoline derivatives
WO2006004795A2 (en) 2004-06-25 2006-01-12 The Johns Hopkins University Angiogenesis inhibitors
WO2006021884A2 (en) 2004-08-26 2006-03-02 Pfizer Inc. Enantiomerically pure aminoheteroaryl compounds as protein kinase inhibitors
US20090047365A1 (en) * 2005-02-28 2009-02-19 Eisai R & D Management Co., Ltd. Novel Concomitant Use of Sulfonamide Compound with Anti-Cancer Agent
US7399335B2 (en) * 2005-03-22 2008-07-15 H.C. Starck Inc. Method of preparing primary refractory metal
AU2007207465B2 (en) 2006-01-18 2012-12-06 Merck Patent Gmbh Specific therapy using integrin ligands for treating cancer
DE102006037158A1 (en) * 2006-08-02 2008-02-14 Bioxsys Gmbh Method for determining the sensitivity of tumors to capecitabine and test kit
US20080051380A1 (en) 2006-08-25 2008-02-28 Auerbach Alan H Methods and compositions for treating cancer
PT2101805E (en) 2007-01-18 2013-01-31 Merck Patent Gmbh Integrin ligands for use in treating cancer
CA2676413A1 (en) * 2007-01-19 2008-07-31 Mallinckrodt Inc. Diagnostic and therapeutic cyclooxygenase-2 binding ligands
JP2010516625A (en) 2007-01-24 2010-05-20 インサート セラピューティクス， インコーポレイテッド Polymer-drug conjugates with tether groups for controlled drug delivery
CN101641599A (en) * 2007-03-23 2010-02-03 霍夫曼-拉罗奇有限公司 APEX as a marker for lung cancer
WO2008138200A1 (en) * 2007-05-11 2008-11-20 Hong Kong University Of Science & Technology Nmda and mc receptor antagonists exhibiting neuroprotective and memory enhancing activities
CN101861319B (en) * 2007-11-16 2013-12-11 宇部兴产株式会社 Benzazepinone compound
CA2740028A1 (en) 2008-01-23 2009-07-30 Herlev Hospital Ykl-40 as a general marker for non-specific disease
CA2739944A1 (en) * 2008-01-23 2009-07-30 Rigshospitalet Classification of individuals suffering from cardiovascular diseases according to survival prognoses as found by measuring the levels of biomarker ykl-40
MX2010011435A (en) 2008-04-18 2011-01-25 Reata Pharmaceuticals Inc Compounds including an anti-inflammatory pharmacore and methods of use.
EP2328923B1 (en) 2008-09-02 2016-01-13 Cedars-Sinai Medical Center Cd133 epitopes
US8580520B2 (en) 2008-09-15 2013-11-12 Herlev Hospital YKL-40 as a marker for gastrointestinal cancers
US9332973B2 (en) 2008-10-01 2016-05-10 Covidien Lp Needle biopsy device with exchangeable needle and integrated needle protection
US11298113B2 (en) 2008-10-01 2022-04-12 Covidien Lp Device for needle biopsy with integrated needle protection
US9782565B2 (en) 2008-10-01 2017-10-10 Covidien Lp Endoscopic ultrasound-guided biliary access system
US8968210B2 (en) 2008-10-01 2015-03-03 Covidien LLP Device for needle biopsy with integrated needle protection
US9186128B2 (en) 2008-10-01 2015-11-17 Covidien Lp Needle biopsy device
ES2618573T3 (en) 2009-05-07 2017-06-21 ImmunoCellular Therapeutics,Ltd CD133 epitopes
ES2507145T3 (en) * 2009-05-14 2014-10-14 Arizona Board Of Regents On Behalf Of University Of Arizona Diagnosis and treatment of carcinoma, based on the genotype of ODC1
JP5572996B2 (en) * 2009-05-15 2014-08-20 宇部興産株式会社 Medicine containing benzazepinone compound as active ingredient
NZ597339A (en) 2009-05-25 2013-10-25 Merck Patent Gmbh Continuous administration of cilengitide in cancer treatments
US8754072B2 (en) 2010-02-12 2014-06-17 Pfizer Inc. Salts and polymorphs of 8-fluoro-2-{4-[(methylamino)methyl]phenyl}-1,3,4,5-tetrahydro-6h-azepino[5,4,3-cd]indol-6-one
US8515525B2 (en) * 2011-08-16 2013-08-20 Women's Imaging Solutions Enterprises Llc Skin adhesive agent for mammography procedures
KR20140103122A (en) 2011-11-17 2014-08-25 넨키 인스티튜트 오브 익스페리멘탈 바이올로지 Compositions and methods for treating glioma
US8716226B2 (en) 2012-07-18 2014-05-06 Saint Louis University 3,5 phenyl-substituted beta amino acid derivatives as integrin antagonists
AU2013292580B2 (en) 2012-07-18 2017-07-20 Saint Louis University Beta amino acid derivatives as integrin antagonists
US20140094432A1 (en) 2012-10-02 2014-04-03 Cerulean Pharma Inc. Methods and systems for polymer precipitation and generation of particles
TWI646091B (en) 2012-12-28 2019-01-01 日商衛斯克慧特股份有限公司 Salt and crystal form
EP2956544B1 (en) 2013-02-14 2017-11-01 Immunocellular Therapeutics Ltd. Cancer vaccines and vaccination methods
WO2014127785A1 (en) 2013-02-20 2014-08-28 Ganymed Pharmaceuticals Ag Combination therapy involving antibodies against claudin 18.2 for treatment of cancer
WO2014150996A1 (en) * 2013-03-15 2014-09-25 Cba Pharma, Inc. Cancer treatment
DK3929196T3 (en) 2013-09-24 2023-09-25 Fujifilm Corp PHARMACEUTICAL COMPOSITION OF A NITROGEN-CONTAINING COMPOUND OR SALT THEREOF OR METAL COMPLEX THEREOF
US20170065723A1 (en) * 2013-09-27 2017-03-09 Cerulean Pharma Inc. Treatment of cancer
EP3094342A4 (en) 2014-01-15 2017-12-27 Nikolai Khodarev Anti-tumor therapy
EP3233829B1 (en) 2014-12-18 2019-08-14 Pfizer Inc Pyrimidine and triazine derivatives and their use as axl inhibitors
AU2016343851B2 (en) 2015-10-30 2022-04-07 Cancer Prevention Pharmaceuticals, Inc. Eflornithine and sulindac, fixed dose combination formulation
US9782370B2 (en) * 2015-12-21 2017-10-10 Gongwin Biopharm Holdings Co., Ltd. Pharmaceutical compositions of benzenesulfonamide derivatives for treatment of adenoid cystic carcinoma
WO2017117130A1 (en) 2015-12-28 2017-07-06 The United States Of America, As Represented By The Secretary, Department Of Health & Human Services Methods for inhibiting human immunodeficiency virus (hiv) release from infected cells
RU2729518C2 (en) 2015-12-30 2020-08-07 Сент-Луис Юниверсити Meta-azacyclic aminobenzoic acid derivatives as pan-integrin antagonists
US10888549B2 (en) 2016-03-07 2021-01-12 The Johns Hopkins University Pharmaceutical agents targeting cancer stem cells
US20170273926A1 (en) * 2016-03-24 2017-09-28 Orbus Therapeutics, Inc. Compositions and methods for use of eflornithine and derivatives and analogs thereof to treat cancers, including gliomas
WO2018023017A1 (en) 2016-07-29 2018-02-01 Janssen Pharmaceutica Nv Methods of treating prostate cancer
US10668039B2 (en) 2016-09-02 2020-06-02 The Children's Medical Center Corporation Methods for treatment of adenoid cystic carcinoma
US10786470B2 (en) 2016-10-06 2020-09-29 Orbus Therapeutics, Inc. Formulations for administration of eflornithine
CN106389429A (en) * 2016-12-02 2017-02-15 郑州莉迪亚医药科技有限公司 Western medicine composition for treating senile dementia and application thereof
WO2019040319A1 (en) * 2017-08-25 2019-02-28 The Regents Of The University Of California Methods of improving cancer chemotherapy
CN111777615B (en) * 2020-07-20 2022-04-19 济南大学 Photodynamic therapy probe for detecting cyclooxygenase 2 and preparation thereof
CN114767868B (en) * 2022-03-30 2023-04-18 宁夏医科大学 Application of COX-2 inhibitor and chemotherapeutic drug in preparation of antitumor drug

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016227A1 (en) * 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP0927555A1 (en) * 1997-12-24 1999-07-07 Sankyo Company Limited Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia

Family Cites Families (94)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2465486A1 (en) 1979-09-21 1981-03-27 Roussel Uclaf NEW APPLICATION USING LH-RH OR AGONISTS
DE3121153A1 (en) 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "USE OF AROMATASE INHIBITORS FOR PROPHYLAXIS AND THERAPY OF PROSTATE HYPERPLASIA"
US4775660A (en) 1984-08-02 1988-10-04 Fernand Labrie Treatment of breast cancer by combination therapy
US4659695A (en) 1985-02-08 1987-04-21 Fernand Labrie Method of treatment of prostate cancer
US4760053A (en) 1984-08-02 1988-07-26 Fernand Labrie Combination therapy for selected sex steroid dependent cancers
US5039805A (en) 1988-12-08 1991-08-13 Hoffmann-La Roche Inc. Novel benzoic and phenylacetic acid derivatives
US5084466A (en) 1989-01-31 1992-01-28 Hoffmann-La Roche Inc. Novel carboxamide pyridine compounds which have useful pharmaceutical utility
CA2008116C (en) 1989-02-23 2001-11-20 Thomas Weller Glycine derivatives
US5770564A (en) 1989-06-16 1998-06-23 Cor Therapeutics, Inc. Platelet aggregation inhibitors
US5061693A (en) 1989-07-28 1991-10-29 Merck & Co., Inc. Fibrinogen receptor antagonists
CA2037153A1 (en) 1990-03-09 1991-09-10 Leo Alig Acetic acid derivatives
US5612311A (en) 1990-04-06 1997-03-18 La Jolla Cancer Research Foundation Method and composition for treating thrombosis
US5721210A (en) 1990-07-09 1998-02-24 Tanabe Seiyaku Co., Ltd. Cyclic cell adhesion modulation compounds
US5229366A (en) 1990-10-23 1993-07-20 Fuji Photo Film Co., Ltd. Peptide-containing polyethylene glycol derivatives and application thereof
AU646966B2 (en) 1991-08-23 1994-03-10 Takeda Chemical Industries Ltd. 2-piperazinone compounds, their production and use
CA2078817A1 (en) 1991-10-18 1993-04-19 Beat A. Imhof Anti-.alpha.6-integrin-antibodies
US5565449A (en) 1991-10-18 1996-10-15 Genentech, Inc. Nonpeptidyl integrin inhibitors having specificity for the GPIIb IIIa receptor
JPH07103148B2 (en) 1991-12-16 1995-11-08 株式会社ディ・ディ・エス研究所 Anthracycline-macrolide complex
US5965132A (en) 1992-03-05 1999-10-12 Board Of Regents, The University Of Texas System Methods and compositions for targeting the vasculature of solid tumors
US5225531A (en) 1992-04-09 1993-07-06 Washington University Hexapeptide Lys Gly Ala Gly Asp Val
US5491129A (en) 1992-07-30 1996-02-13 Yeda Research And Development Co. Ltd. Synthetic peptides derived from vitronectin and pharmaceutical compositions comprising them
US5629343A (en) * 1992-10-02 1997-05-13 Merck & Co., Inc. N-(mercaptoacyl) peptidyl derivatives as antidegenerative agents
JPH06116289A (en) 1992-10-09 1994-04-26 Fuji Photo Film Co Ltd Cell adhesive peptide sequence complex and its use
JPH08503475A (en) * 1992-11-25 1996-04-16 メルク エンド カンパニー インコーポレーテッド Carboxy-peptidyl derivatives as anti-modifying activators
TW301607B (en) 1993-03-09 1997-04-01 Takeda Pharm Industry Co Ltd
DE4310632A1 (en) 1993-04-01 1994-10-06 Merck Patent Gmbh Linear Adhesion Inhibitors
DE4310643A1 (en) 1993-04-01 1994-10-06 Merck Patent Gmbh Cyclic adhesion inhibitors
DK0623615T3 (en) 1993-05-01 1999-12-13 Merck Patent Gmbh Adhesion receptor antagonists
DE4332384A1 (en) 1993-09-23 1995-03-30 Merck Patent Gmbh Adhesion receptor antagonists III
US5536814A (en) 1993-09-27 1996-07-16 La Jolla Cancer Research Foundation Integrin-binding peptides
DE4336758A1 (en) 1993-10-28 1995-05-04 Merck Patent Gmbh Linear Adhesion Inhibitors
DK0656348T3 (en) 1993-12-03 2000-09-11 Hoffmann La Roche Acetic acid derivatives as drugs
JP3750144B2 (en) 1994-01-14 2006-03-01 大正製薬株式会社 3-Aryl thiazoline derivatives
JP3235319B2 (en) 1994-01-14 2001-12-04 大正製薬株式会社 Thiazoline derivatives
DE4405378A1 (en) 1994-02-19 1995-08-24 Merck Patent Gmbh Adhesion receptor antagonists
JPH07285992A (en) 1994-02-25 1995-10-31 Snow Brand Milk Prod Co Ltd New peptide
US5753230A (en) * 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5770565A (en) 1994-04-13 1998-06-23 La Jolla Cancer Research Center Peptides for reducing or inhibiting bone resorption
DE4415310A1 (en) 1994-04-30 1995-11-02 Merck Patent Gmbh Cyclopeptides
WO1995032710A1 (en) 1994-05-27 1995-12-07 Merck & Co., Inc. Compounds for inhibiting osteoclast-mediated bone resorption
US5990112A (en) * 1996-06-18 1999-11-23 Affymax Technologies N.V. Inhibitors of metalloproteases pharmaceutical compositions comprising same and methods of their use
US5510332A (en) 1994-07-07 1996-04-23 Texas Biotechnology Corporation Process to inhibit binding of the integrin α4 62 1 to VCAM-1 or fibronectin and linear peptides therefor
US5464855A (en) 1994-08-09 1995-11-07 Warner-Lambert Company Thiophene-2-carboxamidotetrazoles and pharmaceutical use thereof
US5639726A (en) 1994-09-30 1997-06-17 The Regents Of The University Of Michigan Peptide mediated enhancement of thrombolysis methods and compositions
DK0710657T3 (en) 1994-11-02 1999-05-25 Merck Patent Gmbh Adhesion receptor antagonists
DE4439846A1 (en) 1994-11-08 1996-05-09 Merck Patent Gmbh Adhesion receptor antagonists
US5574026A (en) 1994-12-13 1996-11-12 American Cyanamid Company Methods for inhibiting angiogenesis proliferation of endothelial or tumor cells and tumor growth
JPH08183788A (en) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd 1-oxa-6-azaspiro(2,5)octane derivative
JPH08183752A (en) 1994-12-28 1996-07-16 Sumitomo Pharmaceut Co Ltd Cyclohexane derivative
DE19504954A1 (en) 1995-02-15 1996-08-22 Merck Patent Gmbh Adhesion receptor antagonists
DE19516483A1 (en) 1995-05-05 1996-11-07 Merck Patent Gmbh Adhesion receptor antagonists
US5817750A (en) 1995-08-28 1998-10-06 La Jolla Cancer Research Foundation Structural mimics of RGD-binding sites
ES2161373T3 (en) 1995-08-30 2001-12-01 Searle & Co DERIVATIVES OF META-GUANIDINA, UREA, THIOUREA OR AZACICLICO-AMINOBENZOIC ACID AS INTEGRINE ANTAGONISTS.
US6100423A (en) 1995-08-30 2000-08-08 G. D. Searle & Co. Amino benzenepropanoic acid compounds and derivatives thereof
US6013651A (en) 1995-08-30 2000-01-11 G. D. Searle & Co. Meta-azacyclic amino benzoic acid compounds and derivatives thereof
DE19534016A1 (en) 1995-09-14 1997-03-20 Merck Patent Gmbh Biotin derivatives
DE19534177A1 (en) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclic adhesion inhibitors
EP0765660A3 (en) 1995-09-28 1998-09-23 Takeda Chemical Industries, Ltd. Microcapsules comprising 2-piperazinone-1-acetic acid compounds
DE19539091A1 (en) 1995-10-20 1997-04-24 Thomae Gmbh Dr K New 5-membered heterocyclic compounds
ATE230275T1 (en) 1995-10-25 2003-01-15 Senju Pharma Co ANGIOGENSIS INHIBITOR
HUP9902092A3 (en) * 1995-12-08 2000-12-28 Agouron Pharmaceuticals Inc La Metalloproteinase inhibitor benzenesulfonamide derivatives, intermediates, preparation and use thereof, pharmaceutical compositions containing these compounds
US5760028A (en) 1995-12-22 1998-06-02 The Dupont Merck Pharmaceutical Company Integrin receptor antagonists
DE19626701A1 (en) 1996-07-03 1998-01-08 Hoechst Ag New pyrrolidone, imidazolone, furanone or thiophenone derivatives
PT796855E (en) 1996-03-20 2002-07-31 Hoechst Ag INHIBITION OF REABSORCAO IN BONES AND ANTAGONISTS OF VITRONECTIN
DE69713582T2 (en) 1996-03-29 2003-01-09 Searle & Co Cinnamic acid derivatives and their use as integrin antagonists
DK0889875T3 (en) 1996-03-29 2001-09-03 Searle & Co Cycloproylalkanoic acid derivatives
ATE203515T1 (en) 1996-03-29 2001-08-15 Searle & Co META-SUBSTITUTED PHENYLSULPHONAMIDE DERIVATIVES
ATE212978T1 (en) 1996-03-29 2002-02-15 Searle & Co PARA-SUBSTITUTED PHENYLPROPANE ACID DERIVATIVES AS INTEGRIN ANTAGONISTS
ATE204857T1 (en) 1996-03-29 2001-09-15 Searle & Co META-SUBSTITUTED PHENYLENDER DERIVATIVES AND THEIR USE AS ALPHAVBETA3 INTERGRIN ANTAGONISTS OR INHIBITORS
DE19613933A1 (en) 1996-04-06 1997-10-09 Merck Patent Gmbh Cyclic adhesion inhibitors
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
AU2438297A (en) * 1996-05-09 1997-11-26 Alcon Laboratories, Inc. Combinations of angiostatic compounds
DE19654483A1 (en) 1996-06-28 1998-01-02 Merck Patent Gmbh Phenylalanine derivatives
CN1119321C (en) 1996-07-12 2003-08-27 G·D·瑟尔公司 Asymetric synthesis of chiral beta-amino acids
DE19629816A1 (en) 1996-07-24 1998-01-29 Hoechst Ag New cycloalkyl derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
DE19629817A1 (en) 1996-07-24 1998-01-29 Hoechst Ag New imino derivatives as inhibitors of bone resorption and vitronectin receptor antagonists
UA60311C2 (en) * 1996-10-02 2003-10-15 Смітклайн Бічам Корпорейшн Vitronectin receptor antagonists
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
UA70294C2 (en) * 1996-11-19 2004-10-15 Use of cyclooxygenase-2 inhibitors as anti-angiogeuse of cyclooxygenase-2 inhibitors as anti-angiogenic agents nic agents
DE69739295D1 (en) 1996-12-09 2009-04-23 Merck Patent Gmbh Soluble, recombinant alphaV beta3 adhesion receptor
DE19653646A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Substituted purine derivatives, processes for their preparation, agents containing them and their use
DE19653645A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
DE19653647A1 (en) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin receptor antagonists, their preparation and their use
US5837696A (en) * 1997-01-15 1998-11-17 The Research Foundation Of State University Of New York Method of inhibiting cancer growth
US6017925A (en) * 1997-01-17 2000-01-25 Merck & Co., Inc. Integrin antagonists
WO1998031359A1 (en) * 1997-01-17 1998-07-23 Merck & Co., Inc. Integrin antagonists
AU1110799A (en) * 1997-10-29 1999-05-17 Warner-Lambert Company Method of inhibiting metastases of cancer cells
NZ503485A (en) * 1997-11-14 2002-10-25 G Aromatic sulfone hydroxamic acid metalloprotease inhibitor
EA003095B1 (en) * 1997-12-17 2002-12-26 Мерк Энд Ко., Инк. Integrin receptor antagonists
EP0928793B1 (en) 1998-01-02 2002-05-15 F. Hoffmann-La Roche Ag Thiazole derivatives
US6372719B1 (en) * 1998-03-04 2002-04-16 Jay Cunningham ανβ3 integrin antagonists in combination with chemotherapeutic agents
JP2002511462A (en) * 1998-04-10 2002-04-16 ジー・ディー・サール・アンド・カンパニー Heterocyclic glycyl β-alanine derivatives as vitronectin antagonists
CA2338275A1 (en) * 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
US6277878B1 (en) * 1998-09-07 2001-08-21 Pfizer Inc Substituted indole compounds as anti-inflammatory and analgesic agents

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1998016227A1 (en) * 1996-10-15 1998-04-23 G.D. Searle & Co. Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia
EP0927555A1 (en) * 1997-12-24 1999-07-07 Sankyo Company Limited Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumors, tumor-related disorders and cachexia

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
BIOLOGICAL ABSTRACTS, vol. 00, Philadelphia, PA, US; abstract no. prev199800349798, BARNI, SANDRO (1) ET AL: "Clinical efficacy of the aromatase inhibitor anastrozole in relation to prolactin secretion in heavily pretreated metastatic breast cancer." XP002133936 *
TUMORI, (JAN.-FEB., 1998) VOL. 84, NO. 1, PP. 45-47. *

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9023338B2 (en) 2006-09-26 2015-05-05 Cedars-Sinai Medical Center Cancer stem cell antigen vaccines and methods
US9095538B2 (en) 2006-09-28 2015-08-04 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods
US9433667B2 (en) 2006-09-28 2016-09-06 Cedars-Sinai Medical Center Cancer vaccines and vaccination methods

Also Published As

Publication number Publication date
WO2000038730A2 (en) 2000-07-06
JP2002533387A (en) 2002-10-08
BR9916536A (en) 2002-01-02
ZA200105055B (en) 2002-09-20
WO2000038718A2 (en) 2000-07-06
JP2002533416A (en) 2002-10-08
US6689787B1 (en) 2004-02-10
HUP0104747A3 (en) 2002-12-28
CN1346282A (en) 2002-04-24
HUP0104814A3 (en) 2003-03-28
CN1398189A (en) 2003-02-19
ATE322290T1 (en) 2006-04-15
AU2209800A (en) 2000-07-31
AU2207000A (en) 2000-07-31
JP2002533407A (en) 2002-10-08
KR20010110310A (en) 2001-12-12
JP2002532563A (en) 2002-10-02
PL350291A1 (en) 2002-12-02
EA200100573A1 (en) 2002-02-28
WO2000038717A2 (en) 2000-07-06
BR9916518A (en) 2002-01-29
NO20013156L (en) 2001-08-23
CA2356302A1 (en) 2000-07-06
EP1140192A2 (en) 2001-10-10
EP1140193A2 (en) 2001-10-10
NO20013155D0 (en) 2001-06-22
ZA200105120B (en) 2002-01-07
EA006294B1 (en) 2005-10-27
EA200100572A1 (en) 2002-02-28
EP1140192B1 (en) 2006-04-05
CA2356606A1 (en) 2000-07-06
WO2000038715A2 (en) 2000-07-06
WO2000038665A2 (en) 2000-07-06
NO20013155L (en) 2001-08-22
MXPA01006499A (en) 2002-04-08
EP1140182A2 (en) 2001-10-10
IL143901A0 (en) 2002-04-21
EP1140177A2 (en) 2001-10-10
WO2000038665A3 (en) 2000-11-16
JP2002533404A (en) 2002-10-08
AU2713600A (en) 2000-07-31
CA2356462A1 (en) 2000-07-06
HUP0104747A2 (en) 2002-04-29
TR200102499T2 (en) 2001-12-21
CA2356402A1 (en) 2000-07-06
AU2380500A (en) 2000-07-31
AU2592600A (en) 2000-07-31
AU783992B2 (en) 2006-01-12
EP1140179A2 (en) 2001-10-10
NO20013156D0 (en) 2001-06-22
HUP0104814A2 (en) 2002-04-29
DE69930764D1 (en) 2006-05-18
WO2000038718A3 (en) 2000-11-09
WO2000038786A3 (en) 2001-03-08
AU2713500A (en) 2000-07-31
CZ20012321A3 (en) 2002-10-16
JP2002533406A (en) 2002-10-08
EP1140194A2 (en) 2001-10-10
EP1140183A1 (en) 2001-10-10
AU2210400A (en) 2000-07-31
AU2593600A (en) 2000-07-12
WO2000038717A3 (en) 2001-02-01
IL143870A0 (en) 2002-04-21
JP2002533405A (en) 2002-10-08
WO2000038719A1 (en) 2000-07-06
CA2356426A1 (en) 2000-06-29
EP1140178A2 (en) 2001-10-10
CN1371286A (en) 2002-09-25
WO2000037107A2 (en) 2000-06-29
CA2356748A1 (en) 2000-07-06
PL349216A1 (en) 2002-07-01
WO2000038786A2 (en) 2000-07-06
KR20010109275A (en) 2001-12-08
CZ20012320A3 (en) 2002-10-16
CA2356929A1 (en) 2000-07-06
JP2002533422A (en) 2002-10-08
WO2000037107A3 (en) 2001-02-01
WO2000038715A3 (en) 2001-01-04
CA2356459A1 (en) 2000-07-06

Similar Documents

Publication Publication Date Title
WO2000038730A3 (en) Use of a cyclooxygenase-2 inhibitor and one or more antineoplastic agents for combination therapy in neoplasia
PL349149A1 (en) Combination therapy of radiation and a cox-2 inhibitor for the treatment of neoplasia
AP9901674A0 (en) Method of using cyclooxygenase-2 inhibitors in the prevention of cardiovascular disorders.
WO2005048942A3 (en) Combination therapy comprising a cox-2 inhibitor and an antineoplastic agent
WO2002098444A3 (en) Use of hepcidin for preparing a medicament for treating disorders of iron homeostasis
HK1020261A1 (en) Use of cyclooxygenase-2 inhibitors for the treatment and prevention of tumours, tumour-related disorders and cachexia
ZA200208228B (en) Use of il-18 inhibitors for the treatment and/or prevention of athesclerosis
WO2002003978A3 (en) A COMBINATION OF FBPase INHIBITORS AND ANTIDIABETIC AGENTS USEFUL FOR THE TREATMENT OF DIABETES
WO1998022101A3 (en) Method of using cyclooxygenase-2 inhibitors as anti-angiogenic agents
GB9804886D0 (en) Therapeutic combination
EP1249240A4 (en) Inhibitors against sodium ion absorption, and preventive or therapeutic agents and foods containing the same
WO2004093856A3 (en) Combination of a cox-2 inhibitor and an alkylating-type antineoplastic agent for treatment of neoplasia
WO2001035979A3 (en) Combined pde3 and pde4 inhibitor therapy for the treatment of obesity
WO2002039958A3 (en) Combination therapy using pentafluorobenzenesulfonamides and antineoplastic agents
AU7688998A (en) Use of metalloproteinase inhibitors in the treatment and prevention of pulmonaryemphysema
AU2001277273A1 (en) Methods and agents for treating persistent pain
IL152989A0 (en) Use of riluzole or its salts for preventing and treating ?noleukodystrophy
AUPR172000A0 (en) An agent for treating cardiac disorders

Legal Events

Date Code Title Description
WWE Wipo information: entry into national phase

Ref document number: 99816332.5

Country of ref document: CN

AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

WWE Wipo information: entry into national phase

Ref document number: 1999967543

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 143870

Country of ref document: IL

WWE Wipo information: entry into national phase

Ref document number: 2001/05120

Country of ref document: ZA

Ref document number: 512531

Country of ref document: NZ

Ref document number: 23805/00

Country of ref document: AU

Ref document number: 200105120

Country of ref document: ZA

ENP Entry into the national phase

Ref document number: 2356606

Country of ref document: CA

Ref document number: 2356606

Country of ref document: CA

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: PA/a/2001/006489

Country of ref document: MX

Ref document number: PV2001-2320

Country of ref document: CZ

Ref document number: 200100572

Country of ref document: EA

WWE Wipo information: entry into national phase

Ref document number: 1020017008112

Country of ref document: KR

ENP Entry into the national phase

Ref document number: 2000 590681

Country of ref document: JP

Kind code of ref document: A

WWE Wipo information: entry into national phase

Ref document number: IN/PCT/2001/660/KOL

Country of ref document: IN

WWE Wipo information: entry into national phase

Ref document number: 2001/02499

Country of ref document: TR

WWE Wipo information: entry into national phase

Ref document number: 09857873

Country of ref document: US

WWP Wipo information: published in national office

Ref document number: 1999967543

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1020017008112

Country of ref document: KR

WWP Wipo information: published in national office

Ref document number: PV2001-2320

Country of ref document: CZ

WWR Wipo information: refused in national office

Ref document number: PV2001-2320

Country of ref document: CZ

WWG Wipo information: grant in national office

Ref document number: 1999967543

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 23805/00

Country of ref document: AU

WWR Wipo information: refused in national office

Ref document number: 1020017008112

Country of ref document: KR